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Urine Klotho Is Lower in Critically Ill Patients 
With Versus Without Acute Kidney Injury and 
Associates With Major Adverse Kidney Events
Javier A. Neyra, MD, MSCS1,2,3; Xilong Li, PhD4; Federica Mescia, MD2; Victor Ortiz-Soriano, MD1;  
Beverley Adams-Huet, MS4; Johanne Pastor, BS2; Ming-Chang Hu, MD, PhD2,3; Robert D. Toto, MD3,4; 
Orson W. Moe, MD2,3,5; for the Klotho and Acute Kidney Injury (KLAKI) Study Group
Objectives: Klotho and fibroblast growth factor-23 were recently 
postulated as candidate biomarkers and/or therapeutic targets in 
acute kidney injury. We examined whether urine Klotho and serum 
intact fibroblast growth factor-23 levels were differentially and inde-
pendently associated with major adverse kidney events in critically ill 
patients with and without acute kidney injury.
Design: Single-center, prospective, case-control study.
Setting: ICU in a tertiary medical center.
Patients: Fifty-four acute kidney injury patients and 52 controls with-
out acute kidney injury admitted to the ICU.
Interventions: None.
Measurements and Main Results: Acute kidney injury was defined by 
Kidney Disease: Improving Global Outcomes criteria and included 
only acute kidney injury stage greater than or equal to 2. Controls were 
matched by age, gender, and baseline estimated glomerular filtration 
rate. Paired serum and urine samples were obtained 24–48 hours after 
acute kidney injury diagnosis (cases) or ICU admission (controls). The 
primary outcome was 90-day major adverse kidney events, which was 
the composite of all-cause death, dependence on renal replacement 
therapy, or a 50% or higher decrease in estimated glomerular filtration 
rate from baseline. Major adverse kidney events, which was the com-
posite of all-cause death, dependence on renal replacement therapy, or 
a 50% or higher decrease in estimated glomerular filtration rate from 
baseline. Major adverse kidney events developed in 44 patients (41.5%). 
Patients in whom major adverse kidney events developed had more 
comorbidity, higher acuity of illness scores, and more prevalent acute 
kidney injury. Levels of urine Klotho adjusted by creatinine were lower, 
and serum intact fibroblast growth factor-23 levels were higher in acute 
kidney injury patients versus ICU controls. In adjusted models, the high-
est versus lowest tertile of urine Klotho/creatinine was independently 
associated with an overall 95% lower risk of major adverse kidney events 
(81% lower risk in patients with acute kidney injury). The highest versus 
lowest tertile of serum intact fibroblast growth factor-23 was associated 
with more than 300% higher risk of major adverse kidney events.
Conclusions: Urine Klotho/creatinine levels were significantly lower and 
serum intact fibroblast growth factor-23 levels were significantly higher 
in critically ill patients with acute kidney injury versus matched controls 
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without acute kidney injury. When measured in the first 48 hours of 
ICU admission or acute kidney injury diagnosis, urine Klotho/creatinine 
independently associated with major adverse kidney events, particu-
larly in patients with acute kidney injury. These results show promise 
for testing these biomarkers—individually or in combination—as part of 
novel risk prediction models of renal outcomes in the ICU.
Key Words: acute kidney injury; critical illness; fibroblast growth factor 
23; intensive care unit; Klotho; major adverse kidney events
Acute kidney injury (AKI) is a detrimental syndrome that occurs in approximately 50% of critically ill patients admitted to ICUs (1, 2). AKI is associated with high mor-
bidity, mortality (3, 4), and risk of chronic kidney disease (CKD) 
(5, 6) and end-stage renal disease (ESRD) (7). Discovery and vali-
dation of AKI biomarkers have mostly focused on early AKI rec-
ognition (8, 9), and little is known about their utility to predict 
AKI recovery or subsequent CKD/ESRD risk post-AKI. Kidney 
function examination within 90 days postdischarge in survivors 
of AKI associates with subsequent risk of ESRD and has been pro-
posed as a surrogate endpoint for ESRD after AKI (10).
αKlotho (referred to as “Klotho”) is primarily expressed in the 
kidney (11) and has emerged as a potential therapeutic agent for 
AKI in preclinical studies (12). Transmembrane Klotho is a core-
ceptor for fibroblast growth factor (FGF)-23. The extracellular 
domain of transmembrane Klotho is cleaved by proteases (13–15) 
and released into the circulation (soluble Klotho) and can be mea-
sured in blood and urine (16, 17). Soluble Klotho is not filtered 
by the glomerulus, but traffics via transcytosis across the renal 
tubules, from the basolateral to the luminal side, exerts actions in 
the urine, and is then excreted in the urine (17). Preclinical data 
have shown that Klotho protein replacement or transgenic over-
expression (18–20) can attenuate AKI, promote recovery, and pre-
vent CKD post-AKI (18, 21).
Elevation of plasma FGF23 levels has been described in AKI 
(22, 23) and associates with adverse outcomes post-AKI in criti-
cally ill and cardiac surgery patients (24–26). Impaired renal 
clearance or increased production from bone or other organs is 
potential origins of this elevation (27).
The purpose of the present study was to examine whether urine 
Klotho and serum intact FGF23 levels are different in critically 
ill patients with versus without AKI and if these biomarker lev-
els associate with major adverse kidney events (MAKE). To our 
knowledge, this is the first study in critically ill patients in which 
concomitant measurements of urine Klotho and serum intact 
FGF23 levels were done.
METHODS
Study Design and Participants
Single-center, prospective study of 54 AKI patients and 52 
matched controls without AKI admitted to the ICU at the 
University of Texas Southwestern Hospital from January 2015 
to January 2016. AKI was defined by Kidney Disease: Improving 
Global Outcomes (KDIGO) criteria (28). Only patients with 
AKI stage greater than or equal to 2 were included in the study 
as cases. Controls were frequency matched by age (10-yr inter-
vals), gender, and two-category baseline estimated glomeru-
lar filtration rate (eGFR, calculated using CKD-Epidemiology 
Collaboration (CKD-EPI) equation, ≥ 90 and 60–89 mL/min/ 
1.73 m2) (29). Baseline serum creatinine (SCr) was defined as the 
most recent SCr within the 6-month period before ICU admission.
Inclusion criteria included the following: adults greater than 
or equal to 18 years old, admission to the ICU, and baseline eGFR 
greater than or equal to 60 mL/min/1.73 m2. Exclusion criteria con-
sisted of prior kidney or any other solid organ transplant, ESRD, evi-
dence of AKI before ICU admission, or the presence of uroepithelial 
tumors. The protocol was approved by the Institutional Review 
Board. Informed consent was obtained for all study participants.
Sample Collection
A single-timepoint paired serum and urine samples were obtained 
24–48 hours after AKI diagnosis (cases) or ICU admission (con-
trols). Standardized techniques for serum and urine collection, 
transport, processing, and storage were employed. Biospecimens 
were centrifuged at 1,000g, 4°C for 10 minutes. Serum and urine 
supernatant were aliquoted in codified nonsiliconized cryovials 
and stored at –80°C until biomarker measurements were done by 
laboratory personnel blinded to the study design and data. Urine 
samples were not obtained in seven patients due to anuria.
Laboratory Analyses
Urine Klotho was measured by immunoblotting urine with mono-
clonal anti-Kl1 antibody KM2076 (TransGenic, Kobe, Japan) with 
calibration against Klotho standards (30). Urine Klotho was nor-
malized to creatinine concentration in the same spot urine sample. 
The intra-assay coefficient of variation is 8%. Serum intact FGF23 
was measured using the human Intact FGF23 Enzyme-Linked 
Immunosorbent Assay kit (Immutopics-Quidel, San Diego, CA). 
Urine creatinine was measured by capillary electrophoresis (31). 
Other reported analytes were measured as part of standard of care.
Clinical Data
Data pertaining to demographics, kidney function, comorbidity, 
Charlson index, and critical illness parameters were obtained. 
Acute Physiology and Chronic Health Evaluation (APACHE) II 
and Sequential Organ Failure Assessment (SOFA) scores were 
calculated integrating data from the first day of ICU admission. 
For both APACHE II and SOFA, the points related to SCr were 
subtracted from the total score. Anemia was defined as admission 
hematocrit less than 39% for men and less than 36% for women.
Study Outcome
The observation period was from study enrollment until death or 
90 days for survivors. The primary outcome was 90-day MAKE, 
which consisted of the composite of all-cause death, renal replace-
ment therapy (RRT) dependence, or the decrease in eGFR of 
greater than or equal to 50% from baseline (32). Secondary out-
comes consisted of mechanical ventilation days and hospital days 
and were examined only inhospital survivors to offset the compet-
ing risk of death.
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Statistical Analysis
Categorical data were reported as percentages, and continuous 
data were reported as means ± sd or median (25th–75th percen-
tile). Comparisons across biomarker tertiles for categorical vari-
ables were made using Fisher exact test. For continuous variables, 
analysis of variance was used for Gaussian and Kruskal-Wallis test 
for non-Gaussian distributed data. Comparisons between AKI 
versus no-AKI and MAKE-90 versus no MAKE-90 for categori-
cal variables were made using Fisher exact test. For continuous 
variables, t test was used for Gaussian and Wilcoxon rank-sum 
test for non-Gaussian distributed data. Biomarker data were non-
Gaussian distributed and were therefore natural log transformed.
Multivariable logistic regression models were constructed for 
MAKE-90 as the dependent variable and to evaluate the following 
biomarkers as independent variables: urine Klotho, urine Klotho 
adjusted by urine creatinine (urine Klotho/creatinine), serum 
intact FGF23, and serum intact FGF23 divided by urine Klotho 
adjusted by urine creatinine (FGF23-to-Klotho/creatinine ratio). 
Model 1 included age, sex, and Charlson index. Model 2 included 
variables in Model 1 plus nonrenal APACHE II score. Only one of 
two acuity of illness scores (APACHE II or SOFA) was included 
due to collinearity between variables. Secondary outcomes (hos-
pital days and mechanical ventilation days) were examined only 
in those who survived the hospitalization utilizing negative bino-
mial regression adjusted for Model 2. The two-way interaction 
between AKI status and each study biomarker for its association 
with MAKE-90 was evaluated and found to be nonsignificant 
(p > 0.1 for all biomarkers).
Spearman correlation analysis was performed for each study 
biomarker and preselected biochemical parameters measured less 
than 48 hours apart from the study biomarkers. Two-sided p val-
ues of less than 0.05 indicated statistical significance. SAS 9.4 (SAS 
Institute, Cary, NC) was used for statistical analyses.
Sensitivity Analyses
We examined an alternative and more sensitive definition for the 
primary outcome of MAKE-90, which consisted of the composite 
of all-cause death, RRT dependence, or the decrease in eGFR of 
greater than or equal to 25% from baseline (rather than 50%) (32).
RESULTS
Clinical Characteristics
A total of 106 patients were included in the study, 54 with AKI 
stage greater than or equal to 2 and 52 without AKI (controls). 
When comparing characteristics according to tertiles of urine 
Klotho/creatinine, we observed that patients in the lowest tertile 
of urine Klotho/creatinine had more frequently diabetes, ane-
mia, and dipstick proteinuria greater than or equal to 30 mg/dL. 
Concordantly, patients in the lowest tertile of urine Klotho/cre-
atinine had higher Charlson index scores and higher SOFA and 
APACHE II scores, along with worse critical illness parameters 
when compared with their counterparts (Table 1). As depicted in 
Supplementary Table 1 (Supplemental Digital Content 1, http://
links.lww.com/CCX/A52), patients in the highest tertile of FGF23 
had more frequently anemia and dipstick proteinuria greater 
than or equal to 30 mg/dL, higher Charlson scores, and higher 
APACHE II scores.
Characteristics according to AKI status are reported in 
Supplementary Table 2 (Supplemental Digital Content 2, http://
links.lww.com/CCX/A53). There were no differences in age, 
gender, or baseline eGFR as per study design. However, patients 
with AKI had more frequently anemia, liver disease, and higher 
Charlson scores. Similarly, patients with AKI had higher SOFA 
and APACHE II scores along with worse critical illness param-
eters when compared with those without AKI.
Study Outcomes
A total of 44 patients (41.5%) developed MAKE-90: 33 (75%) died, 
three (6.8%) became RRT dependent, and eight (18.2%) survived, 
were RRT independent but had a decrease in eGFR of greater 
than or equal to 50% from baseline by 90 days postenrollment. 
Patients in whom MAKE-90 developed had higher Charlson 
scores and higher critical illness scores (Supplementary Table 3, 
Supplemental Digital Content 3, http://links.lww.com/CCX/A54). 
MAKE-90 occurred more frequently in patients who suffered 
from AKI (70.4% vs 29.6%; p < 0.0001).
Study Biomarkers According to AKI Status
Urine Klotho (pM) and urine Klotho/creatinine (fmol/mg of cre-
atinine) levels were significantly lower in patients with AKI versus 
without AKI (median [25th–75th percentile], 6.0 [4.9–45.0] vs 
23.0 [5.0–67.4]; p < 0.0001; and 9.2 [3.0–33.6] vs 25.0 [6.0–92.8]; 
p < 0.0001, respectively). Serum intact FGF23 (pg/mL) was sig-
nificantly higher in patients with AKI versus without AKI (139.4 
[10.5–4,844.4] vs 17.4 [4.9–196.0]; p < 0.0001). Similarly, FGF23-
to-Klotho/creatinine ratios were significantly higher in patients 
with AKI versus without AKI (Fig. 1).
Association of Study Biomarkers With MAKE-90
Urine Klotho (pM) and urine Klotho/creatinine (fmol/mg of cre-
atinine) levels were significantly lower in patients who had MAKE-
90 versus those who did not (median [25th–75th percentile], 6.0 
[4.9–54.6] vs 19.0 [4.9–67.4]; p  =  0.0008; and 8.4 [3.0–28.7] vs 
21.2 [4.7–92.8]; p < 0.0001, respectively). Serum intact FGF23 
(pg/mL) was significantly higher in patients who had versus who 
did not have MAKE-90 (89.2 [4.9–3,151.0] vs 22.9 [4.9–4,844.4]; 
p  =  0.0004). Similarly, FGF23-to-Klotho/creatinine ratios were 
significantly higher in patients who had versus who did not have 
MAKE-90 (Fig. 1).
In adjusted models, each one-fold higher urine Klotho/creati-
nine levels was associated with an 83% (95% CI, 60–93%) lower 
risk of developing MAKE-90. In contrast, each one-fold higher 
serum intact FGF23 levels was associated with a 90% (95% CI, 
17–210%) higher risk of developing MAKE-90. Similarly, each 
one-fold increase in the FGF23-to-Klotho/creatinine ratio was 
associated with a 172% (95% CI, 49–396%) higher risk of develop-
ing MAKE-90 (Table 2). When biomarker levels were stratified in 
tertiles, the highest tertile of urine Klotho/creatinine (vs the low-
est tertile) was independently associated with a 95% (95% CI, 75–
99%) lower risk of developing MAKE-90. In contrary, the highest 
tertile of both serum intact FGF23 and the FGF23-to-Klotho/
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creatinine ratio (vs the lowest tertile) was associated with higher 
risk of MAKE-90 (Table 2 and Fig. 2).
There was no statistical interaction between the AKI status 
and the association between the study biomarkers and MAKE-
90 (p > 0.1 for each biomarker). Notably, urine Klotho/creatinine 
was the only biomarker significantly associated with MAKE-90 
in patients with AKI (Supplementary Table 4, Supplemental 
Digital Content 4, http://links.lww.com/CCX/A55). There were 
16 patients (25.8%) who had AKI but did not develop MAKE-90. 
In these patients, urine Klotho/creatinine was significantly higher 
and serum intact FGF23 lower, when compared with those who 
developed MAKE-90 (median [25th–75th percentile], 26.3 [12.4–
92.8] vs 8.4 [3.0–28.7]; p < 0.0001; and 17.4 [4.9–196.0] vs 89.2 
[4.9–3,151.0]; p < 0.0001, respectively).
Association of Study Biomarkers With Secondary 
Outcomes
In adjusted models, urine Klotho and urine Klotho/creatinine lev-
els were inversely correlated with total hospital days and mechani-
cal ventilation days in hospital survivors. In contrast, serum intact 
TABLE 1. Characteristics of Patients According to Tertiles of Urine Klotho/Creatinine
Characteristic Tertile 1 Tertile 2 Tertile 3 p
Range, fmol/mg ≤ 11.4 11.7–21.2 22.3–92.8  
No. of patients 33 33 33  
Demographics
 Age, yr ± sd 56.9 ± 17.3 61.0 ± 14.6 53.5 ± 15.3 0.16
 Women, n (%) 16 (48.5) 11 (33.3) 15 (45.5) 0.44
 White race, n (%) 23 (69.7) 22 (66.7) 24 (72.7) 0.77
 Body mass index, kg/m2, yr ± sd 30.4 ± 9.8 27.5 ± 6.8 27.3 ± 7.5 0.23
Baseline kidney function
 Estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology 
Collaboration  equation), mL/min/1.73 m2, median (IQR)
90.2  
(70.1–100.2)
91.9  
(78.9–100.2)
96.6  
(83.7–103.0)
0.49
 SCr, mg/dL, median (IQR) 0.9 (0.7–1.0) 0.9 (0.6–1.0) 0.9 (0.7–1.0) 0.82
 Dipstick proteinuria > 30 mg/dL, n (%) 24 (72.7) 11 (33.3) 7 (21.2) < 0.0001
Comorbidity
 Diabetes, n (%) 13 (39.4) 6 (18.2) 6 (18.2) 0.09
 Hypertension, n (%) 20 (60.6) 16 (48.5) 19 (57.6) 0.67
 Congestive heart failure, n (%) 11 (33.3) 10 (30.3) 9 (27.3) 0.96
 Chronic obstructive pulmonary disease, n (%) 6 (18.2) 3 (9.1) 6 (18.2) 0.54
 Liver disease, n (%) 11 (33.3) 6 (18.2) 4 (12.1) 0.14
 Anemia, n (%) 29 (87.9) 18 (54.6) 23 (69.7) 0.01
 Cancer, n (%) 15 (45.5) 16 (50.0) 14 (42.4) 0.85
 Charlson index, median (IQR) 5 (2–8) 3 (2–5) 2 (2–4) 0.008
Critical illness parameters
 CFB 72 hr, L, median (IQR) 5.0 (2.1–8.0) 1.7 (–0.1 to 4.3) 1.0 (–0.3 to 2.9) 0.004
 CFB ICU stay, L, median (IQR) 8.5 (0.9–14) 1.7 (–0.1 to 4.6) 1.0 (–2 to 3.5) 0.003
 Pressor or inotrope, n (%) 21 (63.6) 14 (42.4) 11 (33.3) 0.04
 Mechanical ventilation, n (%) 22 (66.7) 15 (45.5) 11 (33.3) 0.03
 Packed RBC transfusion, n (%) 21 (63.6) 13 (39.4) 9 (27.3) 0.01
 Nonrenal Acute Physiology and Chronic Health Evaluation II score 
(the points related to SCr were subtracted from the total score), 
median (IQR)
18 (15–22) 18 (12–20) 11 (7–17) 0.004
 Nonrenal Sequential Organ Failure Assessment score (the points 
related to SCr were subtracted from the total score), median (IQR)
8 (4–11) 6 (1–8) 2 (1–6) 0.0008
CFB = cumulative fluid balance, IQR = interquartile range, SCr = serum creatinine.
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FGF23 and the FGF23-to-Klotho/creatinine ratio were positively 
correlated with total hospital days and mechanical ventilation 
days in hospital survivors (Table 3). The median length of hospital 
stay was 10.5 days (1–63 d) for the 82 patients who survived the 
hospitalization.
Correlation Between Study Biomarkers and Biochemical 
Parameters
Urine Klotho/creatinine levels were positively correlated with 
serum calcium, serum albumin, and serum bicarbonate lev-
els (r = 0.047–0.184; p < 0.05) and negatively correlated with 
serum phosphate and serum magnesium. In contrast, serum 
intact FGF23 levels were positively correlated with serum 
phosphate levels (r  =  0.379; p < 0.001) and negatively corre-
lated with serum albumin, serum bicarbonate, and arterial 
pH (Supplementary Fig. 1, Supplemental Digital Content 5, 
http://links.lww.com/CCX/A56).
Sensitivity Analyses
Similar results were obtained when the MAKE-90 definition 
was modified to the composite of all-cause death, RRT depen-
dence, or the decrease in eGFR of greater than or equal to 25% 
(rather than 50%) from baseline. In adjusted models, each 
one-fold higher urine Klotho/creatinine levels was associated 
with an 83% (95% CI, 60–93%) lower risk of MAKE-90. Each 
one-fold higher serum intact FGF23 levels was associated with 
a 110% (95% CI, 26–251%) higher risk of MAKE-90. Similar 
associations to the primary analysis were observed when bio-
marker levels were stratified in tertiles (Supplementary Table 
5, Supplemental Digital Content 6, http://links.lww.com/
CCX/A57).
DISCUSSION
The new finding of our study is that both urine Klotho/creati-
nine and serum intact FGF23 levels associate with MAKE-90 
in critically ill patients admitted to the ICU. Specifically, we 
found that higher urine Klotho/creatinine levels were associ-
ated with a decreased risk of MAKE-90, whereas higher serum 
intact FGF23 levels were associated with an increased risk of 
MAKE-90 in this subset of critically ill patients. These findings 
are timely and relevant because increased circulating FGF23 
levels (33–35) and reduced Klotho expression (18, 36–38) have 
been consistently described in experimental models of AKI. 
Although higher circulating FGF23 levels have been previously 
associated with human AKI (22, 23) and increased morbidity 
and mortality in critically ill patients (25, 26, 39), data related 
to soluble Klotho levels are scarce (40). Our study builds upon 
evidence that serum intact FGF23 and urine Klotho/creatinine 
levels may inform novel risk prediction models focusing on 
renal outcomes in critically ill patients with and without AKI. In 
addition, our study underpins the relevance of ongoing experi-
mental work targeting therapies to modify circulating levels or 
downstream effects of FGF23 and Klotho pathways in AKI and 
critical illness.
Figure 1. Study biomarkers according to (A) acute kidney injury (AKI) status and (B) major adverse kidney event (MAKE)-90 outcome. All biomarker 
measurements are natural log-transformed (Ln). Cr = creatinine, FGF = fibroblast growth factor.
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Low renal Klotho messenger RNA (mRNA) and protein 
levels have been described in experimental AKI (18, 36–38). 
Interestingly, in murine models of post–ischemia-reperfusion 
injury (IRI) compounded by high-phosphate diet starting 2 
weeks after IRI (CKD was detected functionally and histologi-
cally ≈22 wk post-IRI), renal Klotho mRNA and protein expres-
sion showed a subacute and progressive decline starting at day 
14 post-IRI, particularly in mice exposed to prolonged ischemia 
(41). In the latter model, administration of recombinant Klotho 
protein given for 4 consecutive days beginning 24 hours after IRI 
accelerated kidney recovery, reduced kidney fibrosis, enhanced 
endogenous renal Klotho mRNA and protein expression, and 
attenuated the occurrence of CKD (41). Multiple mechanisms 
of Klotho-related renoprotection have been postulated such as 
suppression of apoptosis (38, 42) and cell senescence (43, 44), 
antifibrosis (37, 45–48), and up-regulation of autophagy (41, 49) 
in renal tubular cells.
Elevated plasma FGF23 levels have been reported in murine 
models of AKI (33–35, 50). Nonetheless, the mechanisms of FGF23 
elevation in AKI are not known. Impaired excretion or catabolism 
of FGF23 by the kidneys or increased production from bone or 
other organs could be reasonable explanations for this elevation 
(33–35, 50–52). Measurement of intact FGF23—the biologically 
active form—is less represented than FGF23 assays with C-terminal 
reagents (nondiscriminatory between full length and C-terminal 
fragments) in human AKI literature. Elevation of FGF23 in AKI 
can augment myofibroblast activation and promote fibrosis via 
activation of transforming growth factor-β pathways (53).
Data related to urine Klotho measurements in human AKI are 
scarce. Hu et al (18) demonstrated lower urine Klotho/creatinine 
TABLE 2. Association of Biomarkers With Major Adverse Kidney Event-90 Outcome (Death, Renal 
Replacement Therapy Dependency, 50% Decrease in Estimated Glomerular Filtration Rate)
Biomarker
Tertile 1 Tertile 2 Tertile 3 Per One-Fold Higher
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Urine Klotho     
 Range, pM ≤ 6.0 6.8–21.1 22.0–67.4  
 No. of patients 36 30 33  
 No. of MAKE-90 22 9 7  
 Model 1 1.00 (Reference) 0.20 (0.06–0.66) 0.21 (0.07–0.67) 0.52 (0.32–0.87)
 Model 2 1.00 (Reference) 0.23 (0.07–0.82) 0.21 (0.06–0.71) 0.50 (0.30–0.86)
Urine Klotho/creatinine     
 Range, fmol/mg ≤ 11.4 11.7–21.2 22.3–92.8  
 No. of patients 33 33 33  
 No. of MAKE-90 25 10 3  
 Model 1 1.00 (Reference) 0.18 (0.05–0.56) 0.04 (0.01–0.19) 0.17 (0.07–0.39)
 Model 2 1.00 (Reference) 0.15 (0.04–0.55) 0.05 (0.01–0.25) 0.17 (0.07–0.40)
Serum FGF23     
 Range, pg/mL ≤ 21.5 22.5–100.9 104.3–4,844.4  
 No. of patients 35 36 35  
 No. of MAKE-90 6 18 20  
 Model 1 1.00 (Reference) 3.74 (1.18–11.79) 4.30 (1.34–13.84) 1.86 (1.17–2.96)
 Model 2 1.00 (Reference) 5.85 (1.62–21.18) 4.48 (1.29–15.53) 1.90 (1.17–3.10)
FGF23-to-Klotho/creatinine ratio     
 Range, loge x –2.93 to –0.14 –0.07 to 2.00 2.01–6.22  
 No. of patients 33 33 33  
 No. of MAKE-90 3 13 22  
 Model 1 1.00 (Reference) 5.29 (1.29–21.65) 12.81 (3.03–54.11) 2.81 (1.58–5.02)
 Model 2 1.00 (Reference) 6.93 (1.54–31.10) 11.11 (2.41–51.29) 2.72 (1.49–4.96)
FGF = fibroblast growth factor, MAKE = major adverse kidney event, OR = odds ratio.
Model 1: adjust for age, sex, Charlson Comorbidity Index; model 2: adjusted for age, sex, Charlson Comorbidity Index, and nonrenal Acute Physiology and Chronic 
Health Evaluation II score.
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levels in hospitalized AKI patients when compared with healthy 
volunteers (4.85 ± 1.69 vs 25.38 ± 4.08 fmol/mg of creatinine; 
p < 0.01). In contrast, Torregrosa et al (54) reported that urine 
Klotho/creatinine levels were not different in patients with AKI 
(cardiac surgery or coronary angiography related) versus no AKI. 
It is important to note that the Klotho assays used were different. 
Nonetheless, concerns regarding a reliable soluble Klotho assay 
have precluded large-scale studies (30).
Elevation of plasma FGF23 levels has been described in human 
AKI (22, 23). In a cohort of 250 adult patients undergoing cardiac 
surgery, Leaf et al (23) reported that plasma C-terminal FGF23 
levels were differentially elevated starting at the end of cardiopul-
monary bypass in patients who did versus who did not develop 
postoperative AKI. In critically ill patients, elevated levels of 
C-terminal FGF23 have been also reported to be independently 
associated with incident AKI (26, 39). In a recent post hoc analy-
sis, critically ill patients with the highest versus lowest quartiles of 
plasma C-terminal and intact FGF23 were found to have higher 
60-day mortality (25).
Our study has important strengths that need to be delineated. 
First, we included patients with well-characterized AKI (KDIGO 
stage ≥ 2) and controls in the ICU that were matched on clinical 
parameters that can potentially affect both the independent and 
dependent variables in the analysis. Second, we used SCr and urine 
output criteria to define AKI, which is particularly appropriate in 
the ICU setting. Third, we adjusted our multivariable analyses for 
appropriate confounders, including objective and comprehensive 
comorbidity and critical illness scores. Fourth, we measured—for 
the first time—serum intact FGF23 and urine Klotho/creatinine 
using paired biospecimens of critically ill patients, which high-
lights their bidirectional relationship in human AKI and their 
association with adverse outcomes. Fifth, we measured urine 
Klotho using a previously reported and validated method that is 
available and can be replicated (30). Finally, our study tested a rel-
evant 90-day renal outcome which is a recommended endpoint 
because it relates to the risk of CKD/ESRD post-AKI (32).
Our study also has limitations. First, although our study sample 
is representative of a heterogeneous ICU population, our study 
design is also susceptible to selection bias because we included 
patients with AKI stage greater than or equal to 2 and correspond-
ing matched controls for prespecified clinical characteristics. 
Further, our sample size is relatively small for the examination 
of associations of study biomarkers with MAKE-90 according 
to AKI status. Nonetheless, we did not find a significant inter-
action between study biomarkers and AKI status for MAKE-90. 
Second, we did not clinically adjudicate etiology of AKI which 
can also provide important information for risk stratification of 
adverse outcome. Third, although we adjusted for confounders 
by comprehensive comorbidity and critical illness scores, residual 
confounding by unmeasured covariates may not have been com-
pletely eliminated. Finally, our study did not specifically test the 
utility (performance) of urine Klotho/creatinine or serum intact 
FGF23 for the prediction of MAKE-90 but identified an important 
bidirectional relationship between the levels of these biomarkers 
measured early during the course of ICU admission or AKI diag-
nosis and subsequent adverse renal outcomes.
Figure 2. Association of biomarkers with major adverse kidney event-90 
outcome (death, renal replacement therapy dependency, 50% decrease in 
estimated glomerular filtration rate). The adjusted odds ratios for the higher 
tertiles (tertiles 2 and 3) of each biomarker are represented in reference to 
the lowest tertile (tertile 1). Cr = creatinine, FGF = fibroblast growth factor, 
OR = odds ratio.
TABLE 3. Associations of Biomarkers With Secondary Outcomesa
Biomarker Outcome β (95% CI) p
Urine Klotho Hospital days –0.18 (–0.36 to –0.0004) 0.05
 MV days –0.62 (–1.05 to –0.19) 0.005
Urine Klotho/creatinine Hospital days –0.27 (–0.47 to –0.08) 0.006
 MV days –0.98 (–1.57 to –0.38) 0.002
Serum FGF23 Hospital days 0.23 (0.13–0.32) < 0.0001
 MV days 0.45 (0.17–0.73) 0.0001
FGF23-to-Klotho/creatinine ratio Hospital days 0.17 (0.10–0.25) < 0.0001
 MV days 0.33 (0.13–0.54) 0.002
FGF = fibroblast growth factor, MV = mechanical ventilation.
aHospital survivors only (n = 82).
Model 2: adjusted for age, sex, Charlson Comorbidity Index, and nonrenal Acute Physiology and Chronic Health Evaluation II score.
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CONCLUSIONS
Urine Klotho/creatinine levels were significantly lower and 
serum intact FGF23 levels were significantly higher in critically 
ill patients with AKI versus matched controls without AKI. When 
measured in the first 48 hours of ICU admission or AKI diagnosis, 
urine Klotho/creatinine independently associated with MAKE, 
particularly in patients with AKI. These results show promise for 
testing these biomarkers—individually or in combination—as 
part of novel risk prediction models of renal outcomes in the ICU. 
Nonetheless, our results need to be validated in a larger sample of 
critically ill patients with and without AKI to further underpin 
the impact of Klotho for diagnostics and therapeutics in AKI and 
critical illness.
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